Homoharringtonine/omacetaxine mepesuccinate: The long and winding road to food and drug administration approval

Hagop M. Kantarjian; Susan O'Brien; Jorge Cortes

doi:10.1016/j.clml.2013.03.017

Homoharringtonine/omacetaxine mepesuccinate: The long and winding road to food and drug administration approval

Hagop M. Kantarjian, Susan O'Brien, Jorge Cortes

Research output: Contribution to journal › Review article › peer-review

86 Scopus citations

Abstract

Homoharringtonine/omacetaxine is a unique agent with a long history of research development. It has been recently approved by the Food and Drug Administration for the treatment of chronic myeloid leukemia after failure of 2 or more tyrosine kinase inhibitors. Research with this agent has spanned over 40 years, with many instructive lessons to cancer research, which are summarized in this review.

Original language	English (US)
Pages (from-to)	530-533
Number of pages	4
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	13
Issue number	5
DOIs	https://doi.org/10.1016/j.clml.2013.03.017
State	Published - Oct 2013
Externally published	Yes

Keywords

CML
Homoharringtonine (HHT)
Omacetaxine mepesuccinate
Treatment

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.clml.2013.03.017

Cite this

@article{d196b8c9c853404dae7405c3c99af195,

title = "Homoharringtonine/omacetaxine mepesuccinate: The long and winding road to food and drug administration approval",

abstract = "Homoharringtonine/omacetaxine is a unique agent with a long history of research development. It has been recently approved by the Food and Drug Administration for the treatment of chronic myeloid leukemia after failure of 2 or more tyrosine kinase inhibitors. Research with this agent has spanned over 40 years, with many instructive lessons to cancer research, which are summarized in this review.",

keywords = "CML, Homoharringtonine (HHT), Omacetaxine mepesuccinate, Treatment",

author = "Kantarjian, {Hagop M.} and Susan O'Brien and Jorge Cortes",

note = "Funding Information: H. Kantarjian and J. Cortes received research grants from ChemGenex. ",

year = "2013",

month = oct,

doi = "10.1016/j.clml.2013.03.017",

language = "English (US)",

volume = "13",

pages = "530--533",

journal = "Clinical Lymphoma",

issn = "2152-2650",

publisher = "Cancer Media Group",

number = "5",

}

TY - JOUR

T1 - Homoharringtonine/omacetaxine mepesuccinate

T2 - The long and winding road to food and drug administration approval

AU - Kantarjian, Hagop M.

AU - O'Brien, Susan

AU - Cortes, Jorge

N1 - Funding Information: H. Kantarjian and J. Cortes received research grants from ChemGenex.

PY - 2013/10

Y1 - 2013/10

N2 - Homoharringtonine/omacetaxine is a unique agent with a long history of research development. It has been recently approved by the Food and Drug Administration for the treatment of chronic myeloid leukemia after failure of 2 or more tyrosine kinase inhibitors. Research with this agent has spanned over 40 years, with many instructive lessons to cancer research, which are summarized in this review.

AB - Homoharringtonine/omacetaxine is a unique agent with a long history of research development. It has been recently approved by the Food and Drug Administration for the treatment of chronic myeloid leukemia after failure of 2 or more tyrosine kinase inhibitors. Research with this agent has spanned over 40 years, with many instructive lessons to cancer research, which are summarized in this review.

KW - CML

KW - Homoharringtonine (HHT)

KW - Omacetaxine mepesuccinate

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84884126310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884126310&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2013.03.017

DO - 10.1016/j.clml.2013.03.017

M3 - Review article

C2 - 23790799

AN - SCOPUS:84884126310

SN - 2152-2650

VL - 13

SP - 530

EP - 533

JO - Clinical Lymphoma

JF - Clinical Lymphoma

IS - 5

ER -

Homoharringtonine/omacetaxine mepesuccinate: The long and winding road to food and drug administration approval

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this